Target intelligence / Profile preview

O-specific lipopolysaccharide of Salmonella enterica serovar Paratyphi A (O-LPS)

Target
O-LPS
Molecular classification
Lipopolysaccharide, Bacterial surface antigen, Polysaccharide, Endotoxin
01

Overview

The O-specific lipopolysaccharide (O-LPS) of Salmonella enterica serovar Paratyphi A is a primary surface antigen and a critical virulence factor for the bacterium [1, 3]. It consists of a lipid A anchor, a core oligosaccharide, and a distal O-antigen polysaccharide chain characterized by the O:2 serogroup specificity, which includes the unique sugar paratose [3, 13]. This molecule plays a vital role in protecting the bacterium from host immune responses, such as complement-mediated killing, and contributes to the pathogenesis of paratyphoid fever [4, 13]. As a major target for vaccine development, the O-specific polysaccharide (OSP) is often conjugated to carrier proteins like CRM197 or tetanus toxoid to enhance immunogenicity, particularly in children [3, 11]. These conjugate vaccines aim to elicit high titers of protective antibodies that facilitate the clearance of the pathogen through bactericidal and opsonophagocytic activities [5, 15]. Understanding the structure and immunological properties of the Paratyphi A O-LPS is essential for addressing the global burden of enteric fever, especially in regions where antibiotic resistance is rising [9, 11].

Other names
O-antigenO-polysaccharideParatyphi A O-antigenO:2 antigenO-specific polysaccharideOSP
02

Mechanism of action

Induction of O-antigen-specific bactericidal and opsonophagocytic antibodies that provide protective immunity against Salmonella Paratyphi A infection.

03

Biological functions

Bacterial cell wall integrityImmune evasionPathogenicityEndotoxin activity
04

Disease associations

Paratyphoid feverInfectionEnteric fever
05

Safety considerations

Endotoxicity of the lipid A componentReactogenicitySerotype-specific protection (lack of cross-protection against S. Typhi)
06

Interacting drugs

O:2-CRM197 conjugate vaccine

2 more in the full profile.

07

Biomarkers

Anti-O:2 IgG antibodiesAnti-LPS IgM antibodiesSerum bactericidal activity (SBA)

Beyond the preview

Go deeper on O-specific lipopolysaccharide of Salmonella enterica serovar Paratyphi A (O-LPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on O-specific lipopolysaccharide of Salmonella enterica serovar Paratyphi A (O-LPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call